Delsite and Nastech Sign Pact to Enhance Intranasal Delivery

Published on: 

DelSite Biotechnologies, Inc. (Irving, TX, www.delsite.com), a wholly-owned subsidiary of Carrington Laboratories, Inc. (Irving, TX, www.carringtonlabs.com), has entered into a non-exclusive technology evaluation agreement with Nastech Pharmaceutical Company, Inc. (Bothell, DC, www.nastech.com), for the purpose of evaluating DelSite's GelSite polymer for enhancing the intranasal delivery of peptide and protein therapeutics.

DelSite Biotechnologies, Inc. (Irving, TX, www.delsite.com), a wholly-owned subsidiary of Carrington Laboratories, Inc. (Irving, TX, www.carringtonlabs.com), has entered into a non-exclusive technology evaluation agreement with Nastech Pharmaceutical Company, Inc. (Bothell, DC, www.nastech.com), for the purpose of evaluating DelSite's GelSite polymer for enhancing the intranasal delivery of peptide and protein therapeutics. Financial terms of the agreement were not disclosed.

GelSite polymer is a novel, naturally occurring, mucoadhesive ionic carbohydrate polymer capable of forming a gel when brought into contact with nasal fluids. Gelling occurs with liquid as well as powder formulations and provides sustained release and prolonged nasal residence time that may enhance the nasal delivery of therapeutics or vaccines.

Advertisement

DelSite has evaluated GelSite polymer for delivery of various protein and peptide therapeutics and vaccine antigens and has completed a series of toxicology studies on this polymer. A drug master file (DMF) for use of GelSite polymer in mucosal applications was filed in 2005 and was recently updated with both CBER and CDER.